The Medical Advisory Board supports us in development and commercialization of our colorectal cancer screening test in the U.S. It will support us through design of our clinical studies, speaking on behalf of the application of DNA methylation technology to colorectal cancer screening in the U.S., advising on product positioning in the U.S. and support inclusion of blood screening assays into screening guidelines promulgated by US American professional societies.

Members:

Richard Wender, MD, is Alumni Professor and Chair of the Department of Family and Community Medicine at Thomas Jefferson University in Philadelphia, PA. A graduate of Princeton University and the University of Pennsylvania School of Medicine, Dr. Wender, directed the Family Medicine residency program at Thomas Jefferson for 10 years and became Vice Chairman of the Department in 1995. He was appointed Chair of the Department in August of 2002. In addition to being a practicing family doctor, his major area of academic focus has been cancer prevention and screening. He was the editor of the American Cancer Society Primary Care Physicians Newsletter for 10 years and is now on the Editorial Advisory Board of CA – A Cancer Journal for Clinicians. Dr. Wender has served in leadership positions of professional societies at the state and national level including co-chair of the Professional Education and Practice Task Group and the Steering Committee of the National Colorectal Cancer Roundtable. Dr. Wender worked with the CDC to develop a national training program for clinicians about colorectal cancer prevention and screening. He is the recipient of the St. George Medal from the American Cancer Society and the Cancer Prevention Laurel for National Leadership from the Cancer Research and Prevention Foundation.

Douglas Rex, MD, is Chancellor's Professor and Professor of Medicine at Indiana University School of Medicine and Director of Endoscopy at Indiana University Hospital. As former Chair, US Multi-Society Task Force on Colorectal Cancer, Dr. Rex has been a leading author on key screening guideline documents.

Deborah Fisher, MD, MHS, is Assistant Professor of Medicine, Duke University and core investigator with the Durham VA Health Services Research and Development Center of Excellence. A recipient of Research Excellence in GI and Liver (REGAL) Award, Dr. Fisher's research agenda is to close the gap between guidelines and actual clinical practice for colorectal cancer prevention and detection. Her NIH and VA funded work has evaluated the process of follow-up care for screening and surveillance, validated self-reported screening status, assessed quality indicators, and explored screening appropriateness.

Philip S. Schoenfeld, M.D., M.Ed., M.Sc., is Associate Professor, Department of Internal Medicine, Director, Training Program in GI Epidemiology University of Michigan. Dr. Schoenfeld's research interests have been centered on colorectal cancer screening with colonoscopy and stool tests, cost-effectiveness of colorectal cancer screening and surveillance, and adoption of colorectal cancer screening guidelines.

Scott Ramsey, M.D., Ph.D. is Associate Professor of Medicine and Health Services, Associate Member, Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center. Dr. Ramsey's research interests have focused on the cost effectiveness analyses of colorectal cancer screening, health economic analyses, and cancer therapy outcomes research.